BSC Medical - Gateway to your medical needsNew and Used Medical Equipment

Latest News

Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
Mon, 11 Dec 2017 15:39:33 GMT

STAINES-UPON-THAMES, United Kingdom, Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Ocera Therapeutics, a clinica...
Biopharmaceuticals, Mergers & Acquisitions
Mallinckrodt, Ocera Therapeutics, hepatic encephalopathy

Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100
Mon, 11 Dec 2017 15:37:23 GMT

PARAMUS, N.J., Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Polaryx Therapeutics, Inc. is a biotech company developing patient-friendly oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other form...
Biopharmaceuticals, Neurology, FDA
Polaryx Therapeutics, Neuronal Ceroid Lipofuscinoses

OncoTartis Closes $6M Financing Round
Mon, 11 Dec 2017 15:34:50 GMT

Proceeds to Support Clinical Trials of Promising Cancer Treatment BUFFALO, N.Y., Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- OncoTartis, Inc., a biotechnology company developing a novel category of anti-cancer drugs, has concluded a $6 m...
Biopharmaceuticals, Oncology, Venture Capital

Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA(R) (aflibercept) Injection for Patients with Wet AMD
Mon, 11 Dec 2017 13:24:35 GMT

TARRYTOWN, N.Y., Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics Licen...
Biopharmaceuticals, Ophthalmology, FDA
Regeneron Pharmaceuticals, EYLEA, aflibercept, macular degeneration

FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
Mon, 11 Dec 2017 13:18:05 GMT

Galcanezumab is the first of three investigational, non-opioid treatments in Lilly's pain portfolio INDIANAPOLIS, Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug A...
Biopharmaceuticals, FDA
Eli Lilly, Galcanezumab, migraine

Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology
Mon, 11 Dec 2017 13:11:35 GMT

INDIANAPOLIS, Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that Kimberly Blackwell, M.D., one of the nation's leading breast cancer researchers, will join Lilly Oncology as vice president of ...
Biopharmaceuticals, Oncology, Personnel
Eli Lilly

Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Mon, 11 Dec 2017 13:05:01 GMT

Ardelyx to Receive Up to $125 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif., Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agre...
Biopharmaceuticals, Gastroenterology, Licensing
Ardelyx, Fosun Pharma, tenapanor

Stryker announces definitive agreement to acquire Entellus
Fri, 08 Dec 2017 15:09:29 GMT

Kalamazoo, Michigan � December 7, 2017 -- (Healthcare Sales & Marketing Network) -- Stryker Corporation (NYSE: SYK) announced today a definitive merger agreement to acquire Entellus Medical, Inc. (NASDAQ: ENTL) for $24.00 per share, or an equity value of a...
Devices, Mergers & Acquisitions
Stryker, Entellus Medical, Multi-Sinus Dilation System, Absorbable Nasal Implant

Impax Receives Tentative FDA Approval of Generic Coreg CR(R) (Carvedilol Phosphate) Extended-Release Capsules
Fri, 08 Dec 2017 13:09:24 GMT

BRIDGEWATER, N.J., Dec. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced it has received tentative U.S. Food and Drug Administration ("FDA") approva...
Biopharmaceuticals, Generics, FDA
Impax Laboratories, Coreg CR, carvedilol

VitalConnect Secures Fifth U.S. FDA Clearance for Patient Monitoring Device
Thu, 07 Dec 2017 16:42:14 GMT

The VitalPatch wearable biosensor will include 5-day wear duration in alignment with nation's average hospital stay SAN JOSE, Calif., Dec. 7, 2017 -- (Healthcare Sales & Marketing Network) -- VitalConnect, Inc., a leader in wearable biosensor technolog...
Devices, Monitoring, FDA
VitalConnect, VitalPatch

Source: HSMN NewsFeed